Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...